Could two antibodies and a pill help women control HIV without daily drugs?

NCT ID NCT05281510

Completed Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two lab-made antibodies (VRC07-523LS and CAP256V2LS) and an immune-boosting pill (vesatolimod) in 20 women with HIV who were already on standard antiretroviral therapy. The goal was to see if the regimen is safe and might help control the virus after stopping daily meds. Participants were monitored for side effects and viral rebound.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VRC07-523LS and CAP256V2LS (antibodies) plus vesatolimod (immune stimulant)
What this could lead to: If successful, this combination might help control HIV without daily pills, pointing toward long-term remission.
What could go wrong: This is a small, early-phase safety study with only 20 women. It may not lead to a practical treatment, and side effects from the immune stimulant or antibodies are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

FRESH Clinical Research Site: Females Rising through Education, Support and Health

Umlazi, 4066, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.